The combination of alnodesertib and irinotecan shows promising efficacy in ATM-negative metastatic colorectal cancer, with a ...
During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.
The investigational, potentially first-in-class agent tinostamustine (EDO-S101) has earned FDA orphan drug designation (ODD) ...
The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient outcomes with targeted therapies. The FDA has approved the OncoMate® MSI Dx ...
The FDA has cleared a phase 3 trial for lacutamab in CTCL, following promising phase 2 results showing durable activity and safety. TELLOMAK 3 will assess progression-free survival with two cohorts: ...
El-Khoueiry, MD, discussed nivolumab plus ipilimumab vs lenvatinib/sorafenib in unresectable HCC. Immunotherapy has become a ...
The FDA has granted fast track designation to the EGFR/HER3 bispecific antibody-drug conjugate (ADC) AVZO-1418 for treatment ...
Zelenectide pevedotin (BT8009) demonstrated a well-tolerated safety profile and promising antitumor activity in patients with ...
The triplet therapy was effective only in patients with nonmutated PIK3CA and ESR1 genes, achieving a median PFS of 9.1 ...
Significant progress in bispecific antibodies, antibody-drug conjugates, and radiopharmaceuticals has been achieved this year ...
In terms of prognostic risk factors, HER2 positivity, BM surgical resection, and diagnosis after 2014 were associated with ...
In patients with metastatic breast cancer, pre-treatment interstitial lung abnormalities (ILAs) and human epidermal growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback